Amid global market volatility, TipRanks offers valuable tools to guide investors. One of the most powerful is the Smart Score, which assigns a ranking of one to ten to stocks and highlights their potential to outperform the broader market. Using this tool, we have identified three standout stocks: HA Sustainable Infrastructure Capital (HASI), Pagaya Technologies (PGY), and Crinetics Pharmaceuticals (CRNX). Each of these has earned a top Smart Score and a Strong Buy rating from Wall Street analysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The TipRanks’ Smart Score rates the stocks on a scale from 1 to 10, with 10 being the highest. The score is based on eight key market factors, including Wall Street analyst ratings, insider transactions, financial blogger opinions, and more. Additionally, the Top Smart Score Stocks list offers a comprehensive selection of stocks rated a perfect 10, along with advanced filtering options.
Let’s dive into the details.
What Is the Target Price for HASI?
HA Sustainable Infrastructure Capital (formerly Hannon Armstrong Sustainable Infrastructure Capital) provides financing solutions for sustainable infrastructure projects, including renewable energy, energy efficiency, and climate-focused investments. Year-to-date, HASI stock has gained over 14%.
Looking ahead, Wall Street analysts remain bullish on its upside potential. Out of 10 analysts covering HASI stock, nine rate it as a Buy. Meanwhile, HASI’s average stock price target of $40.50 suggests a potential upside of 32% from current levels.
Is Pagaya a Good Stock to Buy?
Pagaya Technologies is a fintech company that uses AI and machine learning to manage and optimize investment portfolios and credit risk. It focuses on delivering data-driven financial solutions for institutional investors.
Year-to-date, PGY stock has risen 220%. Wall Street analysts remain optimistic, with 9 out of 10 rating it a Buy. According to TipRanks, the stock has a price target of $38.33, implying over 28% upside from current levels.
Is Crinetics a Good Stock to Buy?
Crinetics is a clinical-stage biotech company focused on developing novel therapies for rare endocrine disorders. So far in 2025, CRNX stock has declined by 18%.
CRNX stock carries a Strong Buy rating, with 15 Buys and one Hold in the past three months. The average stock price target of Crinetics is $80.60, which implies a potential upside of 93%.
